| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| ponatinib | tyrosine-protein kinase abl1 | small molecule | Successful target | TTD , drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
1.86 | approved,investigational | inhibitor |
| ponatinib | breakpoint cluster region protein | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.79 | approved,investigational | inhibitor |
| ponatinib | fibroblast growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.26 | approved,investigational | inhibitor |
| ponatinib | fibroblast growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.65 | approved,investigational | inhibitor |
| ponatinib | fibroblast growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.3 | approved,investigational | inhibitor |
| ponatinib | fibroblast growth factor receptor 4 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.24 | approved,investigational | inhibitor |
| ponatinib | fms-like tyrosine kinase 3 | NA | Successful target | TTD , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.76 | approved | unknown |
| ponatinib | receptor-type tyrosine-protein kinase flt3 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.76 | approved,investigational | inhibitor |
| ponatinib | fms-like tyrosine kinase 3 | NA | Successful target | TTD , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.76 | approved | inhibitor |
| ponatinib | vascular endothelial growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.03 | approved,investigational | inhibitor |
| ponatinib | tyrosine-protein kinase kit | NA | Successful target | TTD , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.43 | approved | unknown |
| ponatinib | mast/stem cell growth factor receptor kit | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.43 | approved,investigational | inhibitor |
| ponatinib | tyrosine-protein kinase lck | small molecule | NA | drugbank | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| ponatinib | tyrosine-protein kinase lyn | small molecule | NA | drugbank | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| ponatinib | platelet-derived growth factor receptor alpha | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.25 | approved,investigational | inhibitor |
| ponatinib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.35 | approved,investigational | inhibitor |
| ponatinib | proto-oncogene c-ret | NA | Successful target | TTD , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.35 | approved | inhibitor |
| ponatinib | proto-oncogene c-ret | NA | Successful target | TTD , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.35 | approved | unknown |
| ponatinib | proto-oncogene tyrosine-protein kinase src | small molecule | NA | drugbank , DGIDB | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.16 | approved,investigational | inhibitor |
| ponatinib | angiopoietin-1 receptor | small molecule | NA | drugbank | Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] Philadelphia Chromosome[MeSHID:D010677] Blast Phase[MeSHID:D001752] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| click here to return to the previous page | ||||||||